Decline in serum carcinoembryonic antigen and cytokeratin 19 fragment during chemotherapy predicts objective response and survival in patients with advanced nonsmall cell lung cancer

Abstract

Objectives: The body adiposity index (BAI) is a proposed alternative to the body mass index (BMI) that has shown good cross‐sectional agreement with percent body fat (%BF) in validation studies. The objective of this study was to examine the ability of BAI to track adiposity change over time in a biracial sample of midlife women. Methods: African‐American (n = 159) and Caucasian (n = 206) women, aged 42–60 years, at the Chicago site of the Study of Women's Health Across the Nation were followed from 2002 to 2008. BAI and BMI were calculated from measurements taken at annual assessments. %BF was quantified using whole‐body dual‐energy X‐ray absorptiometry. Difference scores (BAIΔ, BMIΔ, and %BFΔ) quantified adiposity change over a mean of 1.6 (SD = 0.7) years. Lin's concordance correlation (ρc) and Bland–Altman limits‐of‐agreement assessed agreement between BAI and %BF. Results: In examining adiposity change, BAIΔ showed poor agreement with %BFΔ in the overall sample (ρc = 0.41), African‐American women (ρc = 0.36), and Caucasian women (ρc = 0.43). BAIΔ estimated %BFΔ with minimal bias (+0.4%) but low precision (±6.3%BF limits‐of‐agreement). %BFΔ had weaker correlations with BAIΔ (rs = 0.38–0.48) than with BMIΔ (rs = 0.48–0.59). BAI and BMI showed similar cross‐sectional associations with %BF in the overall sample and within each race (rs > 0.74). Conclusions: We conclude that BAI is less accurate than BMI in tracking adiposity change in midlife women, and would not be a suitable replacement for BMI in most research applications involving adiposity change. Am. J. Hum. Biol., 2012. © 2012 Wiley Periodicals, Inc.

Clinical Observations on the Association Between Diagnosis of Lung Cancer and Serum Tumor Markers in Combination

“…The sensitivily of CYFRA21-1 was 55% -70% for lung cancer , and the specificity was 70% -80%. Therefore it is considered to be the best tumor marker in detection of lung squamous cell carcinoma (Ardizzoni et al, 2006). Our study demonstrated that the sensitivity of CYFRA21-1 in detecting lung cancer was 58.42%,the specificity was 91.52%.Level of CYFRA21-1 in serum of patients with lung cancer were significantly higher than those with lung benign disease and healthy controls suggesting the CYFRA21-1 is important in early diagnosis of lung cancer.…”

Prognostic Value of CYFRA 21-1 and Carcinoembryonic Antigen in Non-Small Cell Lung Cancer

“…Ardizzoni et al [41] outlined that a reduction in CEA and CYFRA 21-1 serum levels (≥ 20%) after 2 cycles of chemotherapy could be regarded as a possible surrogate marker of chemotherapy efficacy in patients with advanced NSCLC. Moreover, Nisman et al [42] reported that declination in CYFRA 21-1 levels (≥ 35%) after two cycles of chemotherapy could be a reliable marker for treatment efficacy and survival.…”

Declines in serum CYFRA21-1 and carcinoembryonic antigen as predictors of chemotherapy response and survival in patients with advanced non-small cell lung cancer

“…Nisman et al (20) found that there was no correlation between radiologic OR and survival, while declines in serum CYFRA21-1 after 2 cycles of chemotherapy were closely related to survival. Ardizzoni et al (21) studied 107 patients with advanced NSCLC and also observed that declines in serum CYFRA21-1 and CEA were closely related to chemotherapy response and survival, whereas radiologic OR had no correlation with survival. Similar to previous studies, our study also demonstrated that the declines in serum CYFRA21-1 and CEA were closely related to chemotherapy response and survival, especially related to radiologic OR.…”